Skip to main content

Advertisement

SpringerLink
Log in

Cutaneous involvement in multiple myeloma and bortezomib

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Alexandrescu DT, Koulova L, Wiernik PH (2005) Unusual cutaneous involvement during plasma cell leukemia phase in a multiple myeloma patient after treatment with thalidomide: a case report and a review of the literature. Clin Exp Dermatol 30:391–394. doi:10.1111/j.1365-2230.2005.01788.x

    Article  PubMed  CAS  Google Scholar 

  2. Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, Cangialosi C, Grasso M, Rossini F, Galli M, Catalano L, Zamagni E, Petrucci MT, De Stefano V, Ceccarelli M, Ambrosini MT, Avonto I, Falco P, Ciccone G, Liberati AM, Musto P, Boccadoro M, Italian Multiple Myeloma Network, GIMEMA (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367:825–831. doi:10.1016/S0140-6736(06)68338-4

    Article  PubMed  CAS  Google Scholar 

  3. Blade’ J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 102:1115–1123. doi:10.1046/j.1365-2141.1998.00930.x

    Article  Google Scholar 

  4. Avigdor A, Raanani P, Levi I, Hardan I, Ben-Bassat I (2001) Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma. Leuk Lymphoma 42:683–687. doi:10.3109/10428190109099330

    Article  PubMed  CAS  Google Scholar 

  5. Laura R, Cibeira MT, Uriburu C, Yantorno S, Salamero O, Blade’ J, Montserrat E (2006) Bortezomib: an effective agent in extramedullary disease in multiple myeloma. Eur J Haematol 76:405–408. doi:10.1111/j.0902-4441.2005.t01-1-EJH2462.x

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology, S. Eugenio Hospital, Tor Vergata University, Rome, Italy

    A. Siniscalchi, G. Del Poeta, P. de Fabritiis & T. Caravita

  2. Department of Pathology, S. Eugenio Hospital, Tor Vergata University, Rome, Italy

    S. Fratoni & G. Santeusanio

  3. Divisione di Ematologia, Ospedale S. Eugenio, Università Tor Vergata, P. le Umanesimo, 10, 00144, Rome, Italy

    A. Siniscalchi

Authors
  1. A. Siniscalchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Fratoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Santeusanio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Del Poeta
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. de Fabritiis
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T. Caravita
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Siniscalchi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Siniscalchi, A., Fratoni, S., Santeusanio, G. et al. Cutaneous involvement in multiple myeloma and bortezomib. Ann Hematol 88, 1137–1139 (2009). https://doi.org/10.1007/s00277-009-0717-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-009-0717-7

Keywords

Search

Navigation